A Dose Finding Clinical Trial of Cabozantinib (XL 184) Administered in Combination With Abiraterone in Castration Resistant Prostate Cancer
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 15 Mar 2017
At a glance
- Drugs Cabozantinib (Primary) ; Abiraterone; Prednisone
- Indications Prostate cancer
- Focus Adverse reactions
- 07 Mar 2017 Planned End Date changed from 1 Sep 2016 to 1 Dec 2017.
- 17 Mar 2016 Planned End Date changed from 1 Sep 2015 to 1 Sep 2016 as per ClinicalTrials.gov record.
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.